If youre still early in your treatment or havent increased your dose yet, be patientslow or nonexistent weight loss is common at first
For example, SCFAs stimulate the secretion of GLP-1 and PYY and, thus, may activate eating-inhibitory and glucose-lowering mechanisms exerting glucometabolic health benefits
HirschWNeeJBallouSPetersenTFriedlanderDLeeHNet al
The formula enhances the secretion of PYY and GLP-1, hormones that naturally signal satiety and delay gastric emptying
BPC-157 is locally acting - targets injury site through growth factor and fibroblast pathways, dosed in micrograms (250500 mcg), given twice daily
This guide is for patients using or considering GLP-1 medications for weight loss, including semaglutide or tirzepatide, who want to understand which side effects are common and which symptoms should lead to a call with a physician